Skip to main content
Premium Trial:

Request an Annual Quote

Admera Health CardioGxOne Panel

Admera Health has launched the CardioGxOne next-generation sequencing panel for inherited cardiovascular disease. Developed as a joint venture between Admera Health and Health in Code, the test detects genomic variations in 213 genes related to familial cardiovascular diseases, and is designed to detect the genetic causes of sudden death in young individuals and athletes, such as cardiomyopathies, long QT, and Marfan syndrome. CardioGxOne combines the genetic and clinical information of more than 85,000 individuals from a proprietary database with a comprehensive interpretive report that is reviewed by specialized cardiology geneticists, Admera said.